Derived from the metastasized neuroblastoma of a young human
female, the SK-N-SH cell line is one of the primary in vitro models for brain cancer drug development and testing of
novel immunotherapies. With neurite outgrowths and modulated differentiation,
SK-N-SH complement dopamine-beta-hydroxylase expression with a physiology that
closely follows that of live neuroblastoma tissue in vivo. With cancer-specific transfection
reagents, research involving the screening of siRNA sequences can show how
RNA interference technology could be used to combat cancer proliferation even
after metastasis.
The SK-N-SH cell line was isolated in 1970 from the brain tissue extracted from a 4-year-old female patient suffering from a neuroblastoma. These cells are ideal as transfection hosts because they are known to express high levels of dopamine-beta-hydroxylase and having a higher doubling time. SK-N-SH are used in biomedical research for certain types of brain cancer. Altogen Biosystems manufactures and prepares a SK-N-SH transfection reagent that is cationic lipid based with a high transfection efficacy. This reagent is proven to establish stable cell lines for reliable yields. Transfection Reagent for SK-N-SH Cells (Neuroblastoma Cells, HTB-11)
Comments
Post a Comment